{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:48:37Z","timestamp":1792014517362,"version":"4.4.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>This is a narrative review to summarize current evidence on use of therapies targeting calcitonin gene-related peptide (CGRP) for children and adolescents with headache disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>The CGRP-targeting therapies have been used in adults for prevention of migraine since 2018. There is one randomized controlled trial (RCT) published on fremanezumab in children age 6\u201317 years old which showed favorable outcome as a preventive treatment for episodic migraine. Several real-world evidence (RWE) studies report on use of CGRP-targeting therapies in patients younger than 18 years old. Several clinical trials are pending for other CGRP-targeting therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There is a small number of RWE studies and one RCT study that shows that CGRP-targeting therapies have potential to be beneficial and safe to use in children and adolescents with headache disorders. Future clinical trials, once completed, will further shed light on efficacy and safety of CGRP-targeting therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11916-026-01567-4","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:08:32Z","timestamp":1792012112000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current Evidence on the Use of Calcitonin Gene-Related Peptide-Targeting Therapies in Children and Adolescents"],"prefix":"10.1007","volume":"30","author":[{"given":"Lauren","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Gelfand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"1567_CR1","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/j.1469-8749.2010.03793.x","volume":"52","author":"I Abu-Arafeh","year":"2010","unstructured":"Abu-Arafeh I, Razak S, Sivaraman B, Graham C. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol. 2010;52:1088\u201397. https:\/\/doi.org\/10.1111\/j.1469-8749.2010.03793.x.","journal-title":"Dev Med Child Neurol"},{"key":"1567_CR2","doi-asserted-by":"publisher","first-page":"333102422113133","DOI":"10.1177\/03331024221131331","volume":"43","author":"C Patterson Gentile","year":"2023","unstructured":"Patterson Gentile C, Aguirre GK, Hershey AD, Szperka CL. Comparison of continuous headache features in youth with migraine, new daily persistent headache, and persistent post-traumatic headache. Cephalalgia. 2023;43:3331024221131331. https:\/\/doi.org\/10.1177\/03331024221131331.","journal-title":"Cephalalgia"},{"key":"1567_CR3","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1177\/0333102420920644","volume":"40","author":"BL Reidy","year":"2020","unstructured":"Reidy BL, et al. Clinic-based characterization of continuous headache in children and adolescents: Comparing youth with chronic migraine to those with new daily persistent headache. Cephalalgia. 2020;40:1063\u20139. https:\/\/doi.org\/10.1177\/0333102420920644.","journal-title":"Cephalalgia"},{"key":"1567_CR4","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/head.12394","volume":"54","author":"PAS Rocha-Filho","year":"2014","unstructured":"Rocha-Filho PAS, Santos PV, Headaches. Quality of Life, and Academic Performance in Schoolchildren and Adolescents. Headache: J Head Face Pain. 2014;54:1194\u2013202. https:\/\/doi.org\/10.1111\/head.12394.","journal-title":"Headache: J Head Face Pain"},{"key":"1567_CR5","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1212\/WNL.0b013e318271f812","volume":"79","author":"MA Arruda","year":"2012","unstructured":"Arruda MA, Bigal ME. Migraine and migraine subtypes in preadolescent children: association with school performance. Neurology. 2012;79:1881\u20138. https:\/\/doi.org\/10.1212\/WNL.0b013e318271f812.","journal-title":"Neurology"},{"key":"1567_CR6","doi-asserted-by":"publisher","unstructured":"Tarantino S, et al. Interictal Cognitive Performance in Children and Adolescents With Primary Headache: A Narrative Review. Front Neurol. 2022;13\u20132022. https:\/\/doi.org\/10.3389\/fneur.2022.898626.","DOI":"10.3389\/fneur.2022.898626"},{"key":"1567_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ana.410330109","volume":"33","author":"PJ Goadsby","year":"1993","unstructured":"Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33:48\u201356. https:\/\/doi.org\/10.1002\/ana.410330109.","journal-title":"Ann Neurol"},{"key":"1567_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.410280213","volume":"28","author":"PJ Goadsby","year":"1990","unstructured":"Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183\u20137. https:\/\/doi.org\/10.1002\/ana.410280213.","journal-title":"Ann Neurol"},{"key":"1567_CR9","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, et al. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017;97:553\u2013622. https:\/\/doi.org\/10.1152\/physrev.00034.2015.","journal-title":"Physiol Rev"},{"key":"1567_CR10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s11916-022-01047-5","volume":"26","author":"S Evers","year":"2022","unstructured":"Evers S. CGRP in Childhood and Adolescence Migraine: (Patho)physiological and Clinical Aspects. Curr Pain Headache Rep. 2022;26:475\u201380. https:\/\/doi.org\/10.1007\/s11916-022-01047-5.","journal-title":"Curr Pain Headache Rep"},{"key":"1567_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/14728222.2020.1724285","volume":"24","author":"AS Wattiez","year":"2020","unstructured":"Wattiez AS, Sowers LP, Russo AF. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. Expert Opin Ther Targets. 2020;24:91\u2013100. https:\/\/doi.org\/10.1080\/14728222.2020.1724285.","journal-title":"Expert Opin Ther Targets"},{"key":"1567_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ana.410230214","volume":"23","author":"PJ Goadsby","year":"1988","unstructured":"Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23:193\u20136. https:\/\/doi.org\/10.1002\/ana.410230214.","journal-title":"Ann Neurol"},{"key":"1567_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s10194-018-0951-2","volume":"19","author":"S Forderreuther","year":"2018","unstructured":"Forderreuther S, Zhang Q, Stauffer VL, Aurora SK, Lainez MJA. Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. J Headache Pain. 2018;19:121. https:\/\/doi.org\/10.1186\/s10194-018-0951-2.","journal-title":"J Headache Pain"},{"key":"1567_CR14","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA. 2018;319:1999\u20132008. https:\/\/doi.org\/10.1001\/jama.2018.4853.","journal-title":"JAMA"},{"key":"1567_CR15","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026\u201337. https:\/\/doi.org\/10.1177\/0333102418759786.","journal-title":"Cephalalgia"},{"key":"1567_CR16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","volume":"21","author":"M Ashina","year":"2022","unstructured":"Ashina M, et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022;21:597\u2013607. https:\/\/doi.org\/10.1016\/S1474-4422(22)00185-5.","journal-title":"Lancet Neurol"},{"key":"1567_CR17","unstructured":"Amgen. Aimovig (erenumab) [package insert]. U.S. Food and Drug Administration https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761077s009lbl.pdf. Revised [February 2021]. Accessed [March 20, 2027]."},{"key":"1567_CR18","unstructured":"Teva Pharmaceuticals. Ajovy (fremanezumab) [package insert]. U.S. Food and Drug Administration https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761089s031lbl.pdf. Revised [August 2025]. Accessed [March 20, 2027]."},{"key":"1567_CR19","unstructured":"Eli Lilly and Company. Emgality (galcanezumab) [package insert]. U.S. Food and Drug Administration https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761089s031lbl.pdf. Revised [March 2025]. Accessed [March 20, 2027]."},{"key":"1567_CR20","unstructured":"Inc. Vyepti (eptinezumab) [package insert]. U.S. Food and Drug Administration https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761119s011lbl.pdf Lundbeck Seattle BioPharmaceuticals, Revised. [October 2025]. Accessed [March 20, 2027]."},{"key":"1567_CR21","unstructured":"AbbVie Inc. Qulipta (atogepant) [package insert]. U.S. Food and Drug Administration https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215206s013lbl.pdf. Revised [September 2025]. Accessed [March 20, 2027]."},{"key":"1567_CR22","unstructured":"Pfizer Labs. Nurtec (rimegepant) [package insert]. U.S. Food and Drug Administration https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/212728s029lbl.pdf. Revised [March 2026]. Accessed [March 20, 2027]."},{"key":"1567_CR23","unstructured":"AbbVie Inc. Ubrelvy (ubrogepant) [package insert]. U.S. Food and Drug Administration https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/211765s012lbl.pdf. Revised [June 2025]. Accessed [March 20, 2027]."},{"key":"1567_CR24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa1813440","volume":"381","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, et al. Trial of Galcanezumab in Prevention of Episodic Cluster Headache. N Engl J Med. 2019;381:132\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1813440.","journal-title":"N Engl J Med"},{"key":"1567_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1056\/NEJMoa2504546","volume":"394","author":"AD Hershey","year":"2026","unstructured":"Hershey AD, et al. Fremanezumab in Children and Adolescents with Episodic Migraine. N Engl J Med. 2026;394:243\u201352. https:\/\/doi.org\/10.1056\/NEJMoa2504546.","journal-title":"N Engl J Med"},{"key":"1567_CR26","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/head.70037","volume":"66","author":"AA Gelfand","year":"2026","unstructured":"Gelfand AA, Szperka CL. What\u2019s in the pipeline for pediatric headache treatment? Headache. 2026;66:548\u201350. https:\/\/doi.org\/10.1111\/head.70037.","journal-title":"Headache"},{"key":"1567_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/head.15087","volume":"66","author":"L Shin","year":"2026","unstructured":"Shin L, et al. Gepants for headache prevention in children and adolescents: A multicenter chart review study. Headache. 2026;66:239\u201348. https:\/\/doi.org\/10.1111\/head.15087.","journal-title":"Headache"},{"key":"1567_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.pediatrneurol.2020.09.014","volume":"114","author":"KA Greene","year":"2021","unstructured":"Greene KA, et al. Calcitonin Gene-Related Peptide Monoclonal Antibody Use for the Preventive Treatment of Refractory Headache Disorders in Adolescents. Pediatr Neurol. 2021;114:62\u20137. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2020.09.014.","journal-title":"Pediatr Neurol"},{"key":"1567_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/head.14452","volume":"63","author":"N Zorrilla","year":"2023","unstructured":"Zorrilla N, Gelfand AA, Irwin SL. Eptinezumab for adolescents with chronic refractory headache: A retrospective chart review. Headache. 2023;63:177\u201382. https:\/\/doi.org\/10.1111\/head.14452.","journal-title":"Headache"},{"key":"1567_CR30","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","volume":"94","author":"FA Russell","year":"2014","unstructured":"Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94:1099\u2013142. https:\/\/doi.org\/10.1152\/physrev.00034.2013.","journal-title":"Physiol Rev"},{"key":"1567_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0163-7258(92)90036-y","volume":"56","author":"DR Poyner","year":"1992","unstructured":"Poyner DR. Calcitonin gene-related peptide: multiple actions, multiple receptors. Pharmacol Ther. 1992;56:23\u201351. https:\/\/doi.org\/10.1016\/0163-7258(92)90036-y.","journal-title":"Pharmacol Ther"},{"key":"1567_CR32","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.pain.2003.09.008","volume":"106","author":"G Juhasz","year":"2003","unstructured":"Juhasz G, et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain. 2003;106:461\u201370. https:\/\/doi.org\/10.1016\/j.pain.2003.09.008.","journal-title":"Pain"},{"key":"1567_CR33","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1212\/WNL.0b013e3182a6cb72","volume":"81","author":"E Cernuda-Moroll\u00f3n","year":"2013","unstructured":"Cernuda-Moroll\u00f3n E, et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013;81:1191\u20136. https:\/\/doi.org\/10.1212\/WNL.0b013e3182a6cb72.","journal-title":"Neurology"},{"key":"1567_CR34","doi-asserted-by":"publisher","unstructured":"Fan P-C, Kuo P-H, Lee MT, Chang S-H, Chiou L-C. Plasma Calcitonin Gene-Related Peptide: A Potential Biomarker for Diagnosis and Therapeutic Responses in Pediatric Migraine. Front Neurol. 2019;10\u20132019. https:\/\/doi.org\/10.3389\/fneur.2019.00010.","DOI":"10.3389\/fneur.2019.00010"},{"key":"1567_CR35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","volume":"22","author":"LH Lassen","year":"2002","unstructured":"Lassen LH, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002;22:54\u201361. https:\/\/doi.org\/10.1046\/j.1468-2982.2002.00310.x.","journal-title":"Cephalalgia"},{"issue":"3","key":"1567_CR36","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/brain\/117.3.427","volume":"117","author":"PJ Goadsby","year":"1994","unstructured":"Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain. 1994;117(3):427\u201334. https:\/\/doi.org\/10.1093\/brain\/117.3.427.","journal-title":"Brain"},{"key":"1567_CR37","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0304-3959(94)00097-x","volume":"60","author":"M Fanciullacci","year":"1995","unstructured":"Fanciullacci M, Alessandri M, Figini M, Geppetti P, Michelacci S. Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain. 1995;60:119\u201323. https:\/\/doi.org\/10.1016\/0304-3959(94)00097-x.","journal-title":"Pain"},{"key":"1567_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s10194-017-0726-1","volume":"18","author":"AL Tyburski","year":"2017","unstructured":"Tyburski AL, Cheng L, Assari S, Darvish K, Elliott MB. Frequent mild head injury promotes trigeminal sensitivity concomitant with microglial proliferation, astrocytosis, and increased neuropeptide levels in the trigeminal pain system. J Headache Pain. 2017;18:16. https:\/\/doi.org\/10.1186\/s10194-017-0726-1.","journal-title":"J Headache Pain"},{"key":"1567_CR39","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1177\/0333102419877662","volume":"39","author":"E Navratilova","year":"2019","unstructured":"Navratilova E, et al. CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in mice. Cephalalgia. 2019;39:1762\u201375. https:\/\/doi.org\/10.1177\/0333102419877662.","journal-title":"Cephalalgia"},{"key":"1567_CR40","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017;377:2123\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1705848.","journal-title":"N Engl J Med"},{"key":"1567_CR41","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1212\/WNL.0000000000010019","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, et al. One-year sustained efficacy of erenumab in episodic migraine. Neurology. 2020;95:e469\u201379. https:\/\/doi.org\/10.1212\/WNL.0000000000010019.","journal-title":"Neurology"},{"key":"1567_CR42","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s10194-022-01514-9","volume":"23","author":"S Yu","year":"2022","unstructured":"Yu S, et al. A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study. J Headache Pain. 2022;23:146. https:\/\/doi.org\/10.1186\/s10194-022-01514-9.","journal-title":"J Headache Pain"},{"key":"1567_CR43","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017;377:2113\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1709038.","journal-title":"N Engl J Med"},{"key":"1567_CR44","doi-asserted-by":"publisher","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine. Neurology. 2020;95:e2487\u201399. https:\/\/doi.org\/10.1212\/WNL.0000000000010600.","journal-title":"Neurology"},{"key":"1567_CR45","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, et al. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol. 2018;75:1080\u20138. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1212.","journal-title":"JAMA Neurol"},{"key":"1567_CR46","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, et al. Galcanezumab in chronic migraine. Neurology. 2018;91:e2211\u201321. https:\/\/doi.org\/10.1212\/WNL.0000000000006640.","journal-title":"Neurology"},{"key":"1567_CR47","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38:1442\u201354. https:\/\/doi.org\/10.1177\/0333102418779543.","journal-title":"Cephalalgia"},{"key":"1567_CR48","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, et al. Efficacy and safety of eptinezumab in patients with chronic migraine. Neurology. 2020;94:e1365\u201377. https:\/\/doi.org\/10.1212\/WNL.0000000000009169.","journal-title":"Neurology"},{"key":"1567_CR49","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.clinthera.2020.11.007","volume":"42","author":"TR Smith","year":"2020","unstructured":"Smith TR, et al. Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1\u00a0Year of Treatment in the PROMISE-1 Study. Clin Ther. 2020;42:2254\u2013e22652253. https:\/\/doi.org\/10.1016\/j.clinthera.2020.11.007.","journal-title":"Clin Ther"},{"key":"1567_CR50","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/head.14051","volume":"61","author":"S Saely","year":"2021","unstructured":"Saely S, Croteau D, Jawidzik L, Brinker A, Kortepeter C, Hypertension. A new safety risk for patients treated with erenumab. Headache: J Head Face Pain. 2021;61:202\u20138. https:\/\/doi.org\/10.1111\/head.14051.","journal-title":"Headache: J Head Face Pain"},{"key":"1567_CR51","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1038\/s41598-025-87421-w","volume":"15","author":"N Lee","year":"2025","unstructured":"Lee N, Ok JH, Rhee S-j, Kim Y. Disproportionality analysis of Raynaud\u2019s phenomenon associated with calcitonin gene-related peptide inhibitors using the Food and Drug Administration adverse event reporting system. Sci Rep. 2025;15:5675. https:\/\/doi.org\/10.1038\/s41598-025-87421-w.","journal-title":"Sci Rep"},{"key":"1567_CR52","doi-asserted-by":"publisher","unstructured":"de Lentsch V, van der Arend S, Maassen BWH, VanDenBrink A, Terwindt GM. Blood Pressure in Patients With Migraine Treated With Monoclonal Anti-CGRP (Receptor) Antibodies. Neurology 99, e1897-e1904, doi:https:\/\/doi.org\/10.1212\/WNL.0000000000201008 (2022).","DOI":"10.1212\/WNL.0000000000201008"},{"key":"1567_CR53","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1177\/0333102420905321","volume":"40","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, et al. Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment. Cephalalgia. 2020;40:935\u201348. https:\/\/doi.org\/10.1177\/0333102420905321.","journal-title":"Cephalalgia"},{"key":"1567_CR54","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, et al. Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397:51\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)32544-7.","journal-title":"Lancet"},{"key":"1567_CR55","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, et al. Rimegepant, an Oral Calcitonin Gene\u2013Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019;381:142\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1811090.","journal-title":"N Engl J Med"},{"key":"1567_CR56","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/head.15002","volume":"66","author":"D Kudrow","year":"2026","unstructured":"Kudrow D, Croop RS, Thiry A, Lipton RB. A 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine. Headache: J Head Face Pain. 2026;66:407\u201316. https:\/\/doi.org\/10.1111\/head.15002.","journal-title":"Headache: J Head Face Pain"},{"key":"1567_CR57","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani J, et al. Atogepant for the Preventive Treatment of Migraine. N Engl J Med. 2021;385:695\u2013706. https:\/\/doi.org\/10.1056\/NEJMoa2035908.","journal-title":"N Engl J Med"},{"key":"1567_CR58","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S0140-6736(23)01049-8","volume":"402","author":"P Pozo-Rosich","year":"2023","unstructured":"Pozo-Rosich P, et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402:775\u201385. https:\/\/doi.org\/10.1016\/S0140-6736(23)01049-8.","journal-title":"Lancet"},{"key":"1567_CR59","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/head.14439","volume":"63","author":"M Ashina","year":"2023","unstructured":"Ashina M, et al. Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial. Headache: J Head Face Pain. 2023;63:79\u201388. https:\/\/doi.org\/10.1111\/head.14439.","journal-title":"Headache: J Head Face Pain"},{"key":"1567_CR60","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/head.13766","volume":"60","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, et al. Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II. Headache. 2020;60:686\u2013700. https:\/\/doi.org\/10.1111\/head.13766.","journal-title":"Headache"},{"key":"1567_CR61","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","volume":"381","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, et al. Ubrogepant for the Treatment of Migraine. N Engl J Med. 2019;381:2230\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1813049.","journal-title":"N Engl J Med"},{"key":"1567_CR62","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/head.14389","volume":"62","author":"R Croop","year":"2022","unstructured":"Croop R, et al. Zavegepant nasal spray for the acute treatment of migraine: A Phase 2\/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache: J Head Face Pain. 2022;62:1153\u201363. https:\/\/doi.org\/10.1111\/head.14389.","journal-title":"Headache: J Head Face Pain"},{"key":"1567_CR63","unstructured":"Pfizer Labs. Zavzpret (zavegepant) [package insert]. U.S. Food and Drug Administration https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761089s031lbl.pdf. Revised [August 2025]. Accessed [March 20, 2027]."},{"key":"1567_CR64","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/s0140-6736(23)01683-5","volume":"402","author":"DW Dodick","year":"2023","unstructured":"Dodick DW, et al. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. Lancet. 2023;402:2307\u201316. https:\/\/doi.org\/10.1016\/s0140-6736(23)01683-5.","journal-title":"Lancet"},{"key":"1567_CR65","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1177\/03331024211007789","volume":"41","author":"O Cohen-Barak","year":"2021","unstructured":"Cohen-Barak O, et al. Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach. Cephalalgia. 2021;41:1065\u201374. https:\/\/doi.org\/10.1177\/03331024211007789.","journal-title":"Cephalalgia"},{"key":"1567_CR66","doi-asserted-by":"publisher","unstructured":"Hershey A, et al. [Abstract] Efficacy and safety of fremanezumab for the preventive treatment of episodic and chronic migraine in children and adolescents: outcomes from two randomized, double-blind, placebo-controlled, phase 3 studies. Cephalalgia. 2025;98. https:\/\/doi.org\/10.1177\/03331024251366059.","DOI":"10.1177\/03331024251366059"},{"key":"1567_CR67","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1111\/head.14959","volume":"65","author":"AD Hershey","year":"2025","unstructured":"Hershey AD, Areberg J, Boserup LP, Lindsten A, Rosen M. Pharmacokinetics and safety of eptinezumab in children and adolescents with migraine. Headache. 2025;65:1573\u201383. https:\/\/doi.org\/10.1111\/head.14959.","journal-title":"Headache"},{"key":"1567_CR68","doi-asserted-by":"publisher","unstructured":"Bandatmakur ASM, et al. Effectiveness and Tolerability of Anti-Calcitonin Gene-Related Peptide Therapy for Migraine and Other Chronic Headaches in Adolescents and Young Adults: A Retrospective Study in the USA. Brain Sci. 2024;14. https:\/\/doi.org\/10.3390\/brainsci14090879.","DOI":"10.3390\/brainsci14090879"},{"key":"1567_CR69","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1177\/2010105820935465","volume":"29","author":"YJ Zhao","year":"2020","unstructured":"Zhao YJ, Ho K-H, Wong PS. Early clinical experience with a monoclonal antibody against the calcitonin gene-related peptide receptor in adolescents with migraine: A case series. Proc Singap Healthc. 2020;29:212\u20134. https:\/\/doi.org\/10.1177\/2010105820935465.","journal-title":"Proc Singap Healthc"},{"key":"1567_CR70","doi-asserted-by":"publisher","first-page":"e33689","DOI":"10.7759\/cureus.33689","volume":"15","author":"M Katsuki","year":"2023","unstructured":"Katsuki M, Kashiwagi K, Kawamura S, Koh A. Monoclonal Antibodies Against the Calcitonin Gene-Related Peptide and Its Receptor in Japanese Adolescents With Migraines. Cureus. 2023;15:e33689. https:\/\/doi.org\/10.7759\/cureus.33689.","journal-title":"Cureus"},{"key":"1567_CR71","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3390\/brainsci15050493","volume":"15","author":"J-H Na","year":"2025","unstructured":"Na J-H, Jeon H, Shim J-E, Lee H, Lee Y-M. Effectiveness and Safety of CGRP-Targeted Therapies Combined with Lifestyle Modifications for Chronic Migraine in Korean Pediatric Patients: A Retrospective Study. Brain Sci. 2025;15:493.","journal-title":"Brain Sci"},{"key":"1567_CR72","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1177\/08830738251374537","volume":"41","author":"A Akbar","year":"2026","unstructured":"Akbar A, Deshpande G, Tripathi S. The Use of Anti-CGRP Medications for Management of Intractable Chronic Daily Headaches in the Pediatric Population: Case Series and Literature Review. J Child Neurol. 2026;41:566\u201373. https:\/\/doi.org\/10.1177\/08830738251374537.","journal-title":"J Child Neurol"},{"key":"1567_CR73","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1212\/WNL.0000000000202606","volume":"100","author":"K Tourlas","year":"2023","unstructured":"Tourlas K, Pavitt S. Safety and Efficacy of Oral Calcitonin Gene-Related Peptide Receptor Antagonists for the Acute Treatment of Migraine in the Pediatric Population (P9-12.010). Neurology. 2023;100:2507. https:\/\/doi.org\/10.1212\/WNL.0000000000202606.","journal-title":"Neurology"},{"key":"1567_CR74","unstructured":"Onifade O, Szperka CL, Safety. & Effectiveness of Gepants for Acute Treatment of Migraine in the Pediatric Population: A Retrospective Chart Analysis. Scottsdale Headache Symposium Frontiers in Headache Research (2023)."},{"key":"1567_CR75","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1212\/WNL.0000000000008105","volume":"93","author":"M Oskoui","year":"2019","unstructured":"Oskoui M, et al. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2019;93:500\u20139. https:\/\/doi.org\/10.1212\/WNL.0000000000008105.","journal-title":"Neurology"},{"key":"1567_CR76","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1212\/WNL.0000000000008095","volume":"93","author":"M Oskoui","year":"2019","unstructured":"Oskoui M, et al. Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2019;93:487\u201399. https:\/\/doi.org\/10.1212\/WNL.0000000000008095.","journal-title":"Neurology"},{"key":"1567_CR77","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/head.12105","volume":"53","author":"AD Hershey","year":"2013","unstructured":"Hershey AD, et al. Childhood and Adolescent Migraine Prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine. Headache. 2013;53:799\u2013816. https:\/\/doi.org\/10.1111\/head.12105.","journal-title":"Headache"},{"key":"1567_CR78","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/head.13025","volume":"57","author":"SW Powers","year":"2017","unstructured":"Powers SW, Hershey AD, Coffey CS. The Childhood and Adolescent Migraine Prevention (CHAMP) Study: What Do We Do Now? Headache. 2017;57:180\u20133. https:\/\/doi.org\/10.1111\/head.13025.","journal-title":"Headache"},{"key":"1567_CR79","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1526-4610.2005.05050.x","volume":"45","author":"DW Lewis","year":"2005","unstructured":"Lewis DW, Winner P, Wasiewski W. The Placebo Responder Rate in Children and Adolescents. Headache: J Head Face Pain. 2005;45:232\u20139. https:\/\/doi.org\/10.1111\/j.1526-4610.2005.05050.x.","journal-title":"Headache: J Head Face Pain"},{"key":"1567_CR80","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s12325-024-03063-w","volume":"42","author":"P Eugeni","year":"2025","unstructured":"Eugeni P, et al. US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review. Adv Ther. 2025;42:1207\u201321. https:\/\/doi.org\/10.1007\/s12325-024-03063-w.","journal-title":"Adv Ther"},{"key":"1567_CR81","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/head.13930","volume":"60","author":"G Berman","year":"2020","unstructured":"Berman G, et al. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine. Headache. 2020;60:1734\u201342. https:\/\/doi.org\/10.1111\/head.13930.","journal-title":"Headache"},{"key":"1567_CR82","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/head.14095","volume":"61","author":"A Jakate","year":"2021","unstructured":"Jakate A, et al. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study. Headache. 2021;61:642\u201352. https:\/\/doi.org\/10.1111\/head.14095.","journal-title":"Headache"},{"key":"1567_CR83","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, et al. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. Headache. 2024;64:333\u201341. https:\/\/doi.org\/10.1111\/head.14692.","journal-title":"Headache"},{"key":"1567_CR84","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u2009\u2013\u20092022 update. J Headache Pain. 2022;23:67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x.","journal-title":"J Headache Pain"},{"key":"1567_CR85","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1111\/head.13414","volume":"58","author":"CL Szperka","year":"2018","unstructured":"Szperka CL, et al. Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents. Headache. 2018;58:1658\u201369. https:\/\/doi.org\/10.1111\/head.13414.","journal-title":"Headache"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-026-01567-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-026-01567-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-026-01567-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:08:33Z","timestamp":1792012113000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-026-01567-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1567"],"URL":"https:\/\/doi.org\/10.1007\/s11916-026-01567-4","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"12 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Amy Gelfand - In the last 24 months, Dr. Gelfand has received royalties from UpToDate (for authorship), and honoraria from Elsevier (for authorship), and the Weill Cornell Neurology Department, Kobenhavns Unversitet, and the College Board (for speaking). She receives a stipend from the American Headache Society for her role as Editor of\n                      Headache\n                      . She receives grant support from PCORI as a member of the Steering Committee for the REACH study and from the UCSF Resource Allocation Program as an investigator. She is also supported by a a generous philanthropic donation made by Nathalie and Nicolas Giauque to the UCSF Child & Adolescent Headache Program.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not include any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","label":"Humans and Animals Rights","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"131"}}